I sent another message to BioVaxys management regarding my recent interest in the Avian influenza (H5N1). The Canadian government is concerned about the spread of Avian flu in domestic animals as well its potential to infect all of the human population. This disease could pose a serious threat to our food sources as well to our future human health!
This cross species jump has already occurred in BC, Canada where a youthful person has become hospitalized and very sick indeed! And perhaps a domestic pet was the lone source of contact!
Any outdoor pet can pick up disease at various random places. And your dog or cat may not be too particular about what they may, choose to eat! This may become a very serious issue for our health care system and as if epidemics are not bad enough, perhaps the Avian flu could lead to another world wide pandemic of a much larger size? That would a catastrophe that even a Trump led American government, would be keeny interested, in trying to prevent!
Other companies are working on this very same problem. So why doesn't BioVaxys consider doing some similar research, perhaps working in some partnership with another biotech like a Zentek or by offering up some helpful licensing agreement with any other similarly interested parties?
If an epidemic of animals began some more significant spread to the human population, perhaps the Canadian and a more reluctant American government might find it most expedient to tackle such a possible dire health issue, directly head on!
Perhaps it would be a good idea to approach both governments now to discuss this most urgent matter? Put that idea in their heads at first like a whisper!
Then if such a storm starts to look more ominous, offer up a more instant solution! But make sure that it works, to be used, right away!
The prevention of a possible pandemic would be a good international effort for any new Trump administration to make!
That might help do wonders to convince the American public about the veracity of the new administration's candor about keeping America healthy and great!
A sick America would need all the migrants that they could get to help keep America, all working great together, once again, strong and free!
Even an elderly and stumbling Biden, wouldn't allow his nation to become weak and die!
Like the former President Roosevelt, crippled by polio, he could send out his orders, straight from a wheel chair to his center of command to fight any war!
In Biden's case, in the case of another possible pandemic situation, this major conflict center would have to become the HHS (US Department of Health and Human Services) under which acts the FDA.
Even with crumbling and withering legs and with a faltering voice, Biden could still have shouted out the orders to this most obedient and loyalist of health centers, under his command!
Just imagine a wheel chaired Biden with a megaphone, locked in hand! That's the kind of force of character that this guy conceals, so very well!
Humble is his nature. Strong and defiant is his resolve!
Is it the same with the new man in office?
Trump claims to be better than Biden! Actions speak louder than words! And that effort must be quick and decisive! But he still has a lot to prove!
And posterity judges those who fail the most at the top with utter contempt!
A good whisper in his ear should be all that a big and swaggering man like Trump, needs to hear!
I posed this question to Biovaxys management: "Have you considering partnering or licensing with a company like Zentek (V.Zen) to get more involved in dealing with the Avian flu (H5N1) epidemic? They have just received a 1.1 million dollar grant from the Canadian government. Perhaps you might also approach the Canadian government yourselves for a similar grant. For instance, perhaps the Canadian defence department might be keenly interested in helping to develop your one shot anthrax vaccine. You have other possible vaccine candidates from your biotech patents that our Canadian government might also consider helping to develop!" https://stockhouse.com/news/press-releases/2024/11/06/zentek-and-triera-biosciences-ltd-receive-1-1-million-government-of-canada GUELPH, ON / ACCESSWIRE / November 6, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd. ("Triera") has received a $1.1 million Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza ("HPAI") A(H5N1).
Highlights:
-
The Government of Canada has identified the life sciences sector as a priority of the Canadian economy and is seeking advanced medical technology solutions to address ongoing challenges
-
Triera was awarded a $1.1 million Government of Canada R&D contract through Innovation, Science and Economic Development Canada's ("ISED") Innovative Solutions Canada ("ISC") program: Health Advanced And Emerging Medical Technologies
-
Triera's multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform
-
Government of Canada testing partners include Health Emergency Readiness Canada ("HERC") within ISED, and Defence Research and Development Canada ("DRDC"), the science and technology organization of the Department of National Defence ("DND")
-
The test will help develop a prophylactic and therapeutic for HPAI A(H5N1) following the multivalent aptamer strategy that successfully produced a SARSCoV-2 aptamer
Triera has proven the capability of the multivalent aptamer platform by developing a universal therapeutic and prophylactic that is effective against all variants of SARSCoV2. The contract will allow Triera to prove the capability for developing a lead candidate for HPAI A(H5N1).
HERC is a new federal organization within ISED dedicated to protecting Canadians against future pandemics and delivering on Canada's life sciences and medical countermeasures readiness objectives. HERC will provide a sustained focus on advancing life sciences industrial capabilities and innovation to respond to health threats, building on significant achievements in the sector since 2020, including $2.2B that has been invested under Canada's Biomanufacturing and Life Sciences Strategy.
DRDC is Canada's defence science, technology, and innovation leader. DRDC develops and delivers new technical solutions and advice to the DND, the Canadian Armed Forces, and safety and security communities. This is accomplished by working with partners in industry, academia, other government departments and international allies.
The contract requires Triera to develop a lead candidate for HPAI A(H5N1) within six months of the project initiation. The lead candidate will be tested for its efficacy as a therapeutic and prophylactic along with its safety profile by the Miller Laboratory at McMaster University.
"We are very pleased that our multivalent aptamer platform has been recognized through this ISC Program Testing Stream. We are working with government organizations that understand the significance of our avian flu program and can promote and support further development of our technology. Upon successful completion, Triera will be eligible for further government investment and recognition from Canada and its key allies," said Greg Fenton, CEO of the Company and Triera.
"The potential for an avian influenza pandemic continues to grow and the consequences of a new variant, which would allow human-to-human transmission, could lead to devastating results," Triera's advisor, Dr. Matthew Miller said, "As with national security, the need for an outbreak response must be regarded as a failure to prevent."
"...Aptamers are short and single-stranded DNA or RNA molecules with highly programmable structures that give them the ability to interact specifically with a large variety of targets, including proteins, cells, and small molecules. Multivalent aptamers refer to molecular constructs that combine two or more identical or different types of aptamers. Multivalency increases the avidity of aptamers, a particularly advantageous feature that allows for significantly increased binding affinities in comparison with aptamer monomers. Another advantage of multivalency is increased aptamer stabilities that confer improved performances under physiological conditions for various applications in clinical settings..."
https://pmc.ncbi.nlm.nih.gov/articles/PMC8956053/
I expect that BioVaxys will make every effort to advance their commercial agenda as soon as possible! There are many approaches that this may take.
America may provide some governmental support to the Biotech industry. But the Canadian government also may be approached for some additional cash!
And there remain plenty of licensing and partnership opportunities here in Canada too!
Perhaps management is already working on many of these issues?
They have already been hard at work, knocking on many different doors!
Canadian government funding is just one door to open. But the dollars, they have to offer, are some of the biggest ones to get! And the Canadian Defence Department may be willing to pay, even more for the best of solutions!
Using many different approaches to funding and working well alone or with an agreeable partner is what any good start up company, needs to do!
But the company needs to do the knocking. Shareholders may only offer suggestions to help them out!
If a whisper doesn't work, then shout it out!
All the best! Java